New Formulation of Varubi Launched for Delayed CINV

Varubi is a highly selective and potent antagonist of human substance P/neurokinin 1 (NK-1) receptors.

Tesaro announced that Varubi (rolapitant) IV has launched for use in combination with other antiemetics in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

Varubi IV is a ready-to-use, single-dose vial that does not require saline, reconstitution, or refrigeration; it is also polysorbate 80-free. Varubi IV is administered up to 2 hours prior to chemotherapy administration in combination with a 5-HT3 receptor antagonist and dexamethasone. 

Related Articles

Varubi, a highly selective and potent human substance P/neurokinin 1 (NK-1) receptor antagonist, is already available as 90mg strength tablets. The injectable emulsion is available as 166.5mg/92.5mL (1.8mg/mL) single-dose vials. 

For more information call (844) 483-7276 or visit